Statement on Novavax commitment to equitable access and transparency

Novavax has worked closely with governments, regulatory authorities, and non-governmental organizations (NGOs) to ensure equitable global access to the Novavax COVID-19 vaccine from the earliest days of its development. As global regulatory discussions advance regarding submissions for authorization of NVX-CoV2373, Novavax is working transparently to balance our commitments, including ensuring access to countries and communities that need it most. 

A hallmark of our commitment to equitable access is our pledge, in conjunction with our partner Serum Institute of India, to supply a cumulative 1.1 billion doses of our vaccine to the COVAX Facility, the global vaccine-sharing platform that is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), the Vaccine Alliance (Gavi), and the World Health Organization (WHO), alongside key delivery partner UNICEF. COVAX aims to accelerate the development and manufacture of COVID-19 vaccines and to guarantee fair and equitable access for every country in the world.

To deliver on our supply commitments, Novavax mobilized a global manufacturing network with sites now routinely producing high-quality vaccine doses at commercial scale at multiple sites across the world. Our global supply chain is expected to achieve a capacity of 150 million doses per month by the end of the fourth quarter.

Novavax has advanced many efforts to ensure fair and equitable access to low- and middle-income countries all over the world because we believe that no one is safe from COVID-19 until everyone is safe. As such, we remain focused with urgency on bringing our vaccine to people in need around the globe.